{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:09:13Z","timestamp":1774076953704,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40123-023-00860-4","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T07:01:33Z","timestamp":1704524493000},"page":"615-633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Qualitative Research to Understand the Patient Experience and Evaluate Content Validity of the Chronic Ocular Pain Questionnaire (COP-Q)"],"prefix":"10.1007","volume":"13","author":[{"given":"Paul M.","family":"Karpecki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9887-6956","authenticated-orcid":false,"given":"Amy","family":"Findley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte J.","family":"Sloesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5975-8032","authenticated-orcid":false,"given":"Nicola","family":"Hodson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9914-8934","authenticated-orcid":false,"given":"Sarah","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0345-2523","authenticated-orcid":false,"given":"Rob","family":"Arbuckle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Montecchi-Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3799-6521","authenticated-orcid":false,"given":"Christel","family":"Naujoks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedram","family":"Hamrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"key":"860_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jtos.2022.08.005","volume":"26","author":"A Galor","year":"2022","unstructured":"Galor A, Hamrah P, Haque S, Attal N, Labetoulle M. Understanding chronic ocular surface pain: an unmet need for targeted drug therapy. Ocul Surf. 2022;26:148\u201356.","journal-title":"Ocul Surf"},{"issue":"4","key":"860_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40135-017-0152-1","volume":"5","author":"DS Jacobs","year":"2017","unstructured":"Jacobs DS. Diagnosis and treatment of ocular pain: the ophthalmologist\u2019s perspective. Curr Ophthalmol Rep. 2017;5(4):271\u20135.","journal-title":"Curr Ophthalmol Rep"},{"issue":"3","key":"860_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40123-020-00263-9","volume":"9","author":"D Mehra","year":"2020","unstructured":"Mehra D, Cohen NK, Galor A. Ocular surface pain: a narrativereview. Ophthalmol Therapy. 2020;9(3):1\u201321.","journal-title":"Ophthalmol Therapy"},{"issue":"6","key":"860_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40265-020-01282-3","volume":"80","author":"H Dermer","year":"2020","unstructured":"Dermer H, Lent-Schochet D, Theotoka D, et al. A review of management strategies for nociceptive and neuropathic ocular surface pain. Drugs. 2020;80(6):547\u201371.","journal-title":"Drugs"},{"issue":"4","key":"860_CR5","first-page":"746","volume":"17","author":"JP Kalangara","year":"2016","unstructured":"Kalangara JP, Galor A, Levitt RC, Felix ER, Alegret R, Sarantopoulos CD. Burning eye syndrome: do neuropathic pain mechanisms underlie chronic dry eye? Pain Med. 2016;17(4):746\u201355.","journal-title":"Pain Med"},{"issue":"3","key":"860_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40123-019-0188-4","volume":"8","author":"N Cook","year":"2019","unstructured":"Cook N, Mullins A, Gautam R, et al. Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol Ther. 2019;8(3):407\u201320.","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"860_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/ACI.0000000000000389","volume":"17","author":"HH Andersen","year":"2017","unstructured":"Andersen HH, Yosipovitch G, Galor A. Neuropathic symptoms of the ocular surface: dryness, pain, and itch. Curr Opin Allergy Clin Immunol. 2017;17(5):373\u201381.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"8","key":"860_CR8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1136\/bjophthalmol-2016-309193","volume":"101","author":"M Labetoulle","year":"2017","unstructured":"Labetoulle M, Rolando M, Baudouin C, van Setten G. Patients\u2019 perception of DED and its relation with time to diagnosis and quality of life: an international and multilingual survey. Br J Ophthalmol. 2017;101(8):1100\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"860_CR9","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamaophthalmol.2018.3352","volume":"136","author":"IJ Saldanha","year":"2018","unstructured":"Saldanha IJ, Petris R, Han G, Dickersin K, Akpek EK. Research questions and outcomes prioritized by patients with dry eye. JAMA Ophthalmol. 2018;136(10):1170\u20139.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"860_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtos.2017.10.001","volume":"16","author":"A Galor","year":"2018","unstructured":"Galor A, Moein HR, Lee C, et al. Neuropathic pain and dry eye. Ocul Surf. 2018;16(1):31\u201344.","journal-title":"Ocul Surf"},{"issue":"11","key":"860_CR11","first-page":"29","volume":"153","author":"P Karpecki","year":"2019","unstructured":"Karpecki P. When the pain won\u2019t go away: early diagnosis is key to helping patients overcome neuropathic pain associated with dry eye disease. Rev Optom. 2019;153(11):29\u201331.","journal-title":"Rev Optom"},{"issue":"2","key":"860_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","volume":"1","author":"M Uchino","year":"2013","unstructured":"Uchino M, Schaumberg DA. Dry eye disease: impact on quality of life and vision. Curr Ophthalmol Rep. 2013;1(2):51\u20137.","journal-title":"Curr Ophthalmol Rep"},{"issue":"3","key":"860_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","volume":"143","author":"B Miljanovi\u0107","year":"2007","unstructured":"Miljanovi\u0107 B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409\u201315.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"860_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jtos.2019.12.004","volume":"18","author":"AN Siedlecki","year":"2020","unstructured":"Siedlecki AN, Smith SD, Siedlecki AR, Hayek SM, Sayegh RR. Ocular pain response to treatment in dry eye patients. Ocul Surf. 2020;18(2):305\u201311.","journal-title":"Ocul Surf"},{"key":"860_CR15","unstructured":"US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed Feb 2023."},{"key":"860_CR16","unstructured":"US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. Guidance for industry, administrative staff, and other stakeholders (Guidance 2). 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients. Accessed Feb 2023."},{"issue":"7","key":"860_CR17","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.ophtha.2016.03.006","volume":"123","author":"Y Qazi","year":"2016","unstructured":"Qazi Y, Hurwitz S, Khan S, Jurkunas UV, Dana R, Hamrah P. Validity and reliability of a novel ocular pain assessment survey (OPAS) in quantifying and monitoring corneal and ocular surface pain. Ophthalmology. 2016;123(7):1458\u201368.","journal-title":"Ophthalmology"},{"issue":"5","key":"860_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/09273940701486803","volume":"15","author":"F \u00d6zcura","year":"2007","unstructured":"\u00d6zcura F, Aydin S, Helvaci MR. Ocular surface disease index for the diagnosis of dry eye syndrome. Ocul Immunol Inflamm. 2007;15(5):389\u201393.","journal-title":"Ocul Immunol Inflamm"},{"issue":"11","key":"860_CR19","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1167\/iovs.10-5341","volume":"51","author":"C McAlinden","year":"2010","unstructured":"McAlinden C, Pesudovs K, Moore JE. The development of an instrument to measure quality of vision: the quality of vision (QoV) questionnaire. Invest Ophthalmol Vis Sci. 2010;51(11):5537\u201345.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"860_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1477-7525-9-111","volume":"9","author":"L Abetz","year":"2011","unstructured":"Abetz L, Rajagopalan K, Mertzanis P, et al. Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients. Health Qual Life Outcomes. 2011;9(1):111.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"860_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.pain.2003.12.024","volume":"108","author":"D Bouhassira","year":"2004","unstructured":"Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the neuropathic pain symptom inventory. Pain. 2004;108(3):248\u201357.","journal-title":"Pain"},{"issue":"1","key":"860_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","volume":"5","author":"DA Schaumberg","year":"2007","unstructured":"Schaumberg DA, Gulati A, Mathers WD, et al. Development and validation of a short global dry eye symptom index. Ocul Surf. 2007;5(1):50\u20137.","journal-title":"Ocul Surf"},{"issue":"10","key":"860_CR23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamaophthalmol.2013.4503","volume":"131","author":"Y Sakane","year":"2013","unstructured":"Sakane Y, Yamaguchi M, Yokoi N, et al. Development and validation of the dry eye-related quality-of-life score questionnaire. JAMA Ophthalmol. 2013;131(10):1331\u20138.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"860_CR24","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119(7):1050\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"860_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"860_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839\u201342.","journal-title":"Value Health"},{"issue":"1","key":"860_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough?: An experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382.","journal-title":"Field Methods"},{"key":"860_CR28","unstructured":"Atlas.ti software version 8 [computer program]. 2013. Berlin: Atlas.ti"},{"issue":"10","key":"860_CR29","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ, Johnston M, Robertson C, et al. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25(10):1229\u201345.","journal-title":"Psychol Health"},{"key":"860_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.clinpsy.3.022806.091415","volume":"4","author":"S Shiffman","year":"2008","unstructured":"Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1\u201332.","journal-title":"Annu Rev Clin Psychol"},{"issue":"7","key":"860_CR31","doi-asserted-by":"publisher","first-page":"A572","DOI":"10.1016\/j.jval.2014.08.1914","volume":"17","author":"K Rudell","year":"2014","unstructured":"Rudell K, Tatlock S, Panter C, Arbuckle R, Symonds T. Assessing the methodological value of digital real-time collection of qualitative content in supporting in-depth qualitative interviews exploring the symptoms and impacts of gout on health-related quality of life. Value Health. 2014;17(7):A572.","journal-title":"Value Health"},{"issue":"5","key":"860_CR32","doi-asserted-by":"publisher","first-page":"R177","DOI":"10.1186\/ar3141","volume":"12","author":"W Zhang","year":"2010","unstructured":"Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire\u2013general health version in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R177.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"860_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00019053-200725050-00003","volume":"25","author":"P Wahlqvist","year":"2007","unstructured":"Wahlqvist P, Guyatt GH, Armstrong D, et al. The Work Productivity and Activity Impairment Questionnaire for patients with gastroesophageal reflux disease (WPAI-GERD): responsiveness to change and English language validation. Pharmacoeconomics. 2007;25(5):385\u201396.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"860_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/1756-185X.13801","volume":"23","author":"JK Phang","year":"2020","unstructured":"Phang JK, Kwan YH, Fong W, et al. Validity and reliability of Work Productivity and Activity Impairment among patients with axial spondyloarthritis in Singapore. Int J Rheum Dis. 2020;23(4):520\u20135.","journal-title":"Int J Rheum Dis"},{"key":"860_CR35","unstructured":"Reilly Associates. WPAI general information. 2019. http:\/\/www.reillyassociates.net\/WPAI_General.html. Accessed Feb 2023."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00860-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-023-00860-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00860-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T15:12:08Z","timestamp":1705158728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-023-00860-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["860"],"URL":"https:\/\/doi.org\/10.1007\/s40123-023-00860-4","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,6]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paul Karpecki is an employee of Kentucky Eye Institute and the University of Pikeville Kentucky College of Optometry, Kentucky, USA. Brigitte J. Sloesen and Christel Naujoks are employees of Novartis Pharma AG, Basel, Switzerland. Paul O\u2019Brien was an employee of Novartis Ireland Ltd. at the time of performing the research and preparing the manuscript, and is currently an employee of ViiV Healthcare. Michela Montecchi-Palmer was an employee of Novartis Pharma AG at the time of performing the research and preparing the manuscript, and is currently an employee of Alcon. Nicola Hodson, Sarah Bentley, and Rob Arbuckle are employees of Adelphi Values, a health outcomes agency commissioned by Novartis Pharma AG to conduct this research. Amy Findley was an employee of Adelphi Values at the time the work was performed, and is now an employee of Novo Nordisk. Pedram Hamrah is an employee of the Department of Ophthalmology, Tufts University School of Medicine, Boston, USA. All authors declare that there are no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval and oversight were provided by Western Copernicus Group Independent Review Board (WCG IRB, reference: 1284816), a centralized IRB, to conduct qualitative interviews and daily diary app task activity in the USA. All participants provided oral and written informed consent prior to the conduct of any research activities. The research was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}